Clinical Trial: Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft
Brief Summary: Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
Detailed Summary:
Sponsor: Abgenix
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Abgenix
Dates:
Date Received: May 6, 2002
Date Started: October 1999
Date Completion: June 2003
Last Updated: June 23, 2005
Last Verified: July 2003